Literature DB >> 27366225

Novel perspectives on therapeutic modulation of the gut microbiota.

Justin L McCarville1, Alberto Caminero1, Elena F Verdu2.   

Abstract

The gut microbiota contributes to the maintenance of health and, when disrupted, may drive gastrointestinal and extragastrointestinal disease. This can occur through direct pathways such as interaction with the epithelial barrier and mucosal immune system or indirectly via production of metabolites. There is no current curative therapy for chronic inflammatory conditions such as inflammatory bowel disease, which are complex multifactorial disorders involving genetic predisposition, and environmental triggers. Therapies are directed to suppress inflammation rather than the driver, and these approaches are not devoid of adverse effects. Therefore, there is great interest in modulation of the gut microbiota to provide protection from disease. Interventions that modulate the microbiota include diet, probiotics and more recently the emergence of experimental therapies such as fecal microbiota transplant or phage therapy. Emerging data indicate that certain bacteria can induce protective immune responses and enhance intestinal barrier function, which could be potential therapeutic targets. However, mechanistic links and specific therapeutic recommendations are still lacking. Here we provide a pathophysiological overview of potential therapeutic applications of the gut microbiota.

Entities:  

Keywords:  fecal microbiota transplant; inflammatory bowel disease; irritable bowel syndrome; microbiota; prebiotics; probiotics

Year:  2016        PMID: 27366225      PMCID: PMC4913331          DOI: 10.1177/1756283X16637819

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  138 in total

1.  Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells.

Authors:  Yukihiro Furusawa; Yuuki Obata; Shinji Fukuda; Takaho A Endo; Gaku Nakato; Daisuke Takahashi; Yumiko Nakanishi; Chikako Uetake; Keiko Kato; Tamotsu Kato; Masumi Takahashi; Noriko N Fukuda; Shinnosuke Murakami; Eiji Miyauchi; Shingo Hino; Koji Atarashi; Satoshi Onawa; Yumiko Fujimura; Trevor Lockett; Julie M Clarke; David L Topping; Masaru Tomita; Shohei Hori; Osamu Ohara; Tatsuya Morita; Haruhiko Koseki; Jun Kikuchi; Kenya Honda; Koji Hase; Hiroshi Ohno
Journal:  Nature       Date:  2013-11-13       Impact factor: 49.962

Review 2.  Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics.

Authors:  G R Gibson; M B Roberfroid
Journal:  J Nutr       Date:  1995-06       Impact factor: 4.798

3.  Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial.

Authors:  Kate Costeloe; Pollyanna Hardy; Edmund Juszczak; Mark Wilks; Michael R Millar
Journal:  Lancet       Date:  2015-11-28       Impact factor: 79.321

4.  Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers.

Authors:  Luying Peng; Zhong-Rong Li; Robert S Green; Ian R Holzman; Jing Lin
Journal:  J Nutr       Date:  2009-07-22       Impact factor: 4.798

Review 5.  Resistant starches for the management of metabolic diseases.

Authors:  Laure B Bindels; Jens Walter; Amanda E Ramer-Tait
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2015-11       Impact factor: 4.294

6.  Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease.

Authors:  Lauren A Zenewicz; George D Yancopoulos; David M Valenzuela; Andrew J Murphy; Sean Stevens; Richard A Flavell
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

7.  Linking long-term dietary patterns with gut microbial enterotypes.

Authors:  Gary D Wu; Jun Chen; Christian Hoffmann; Kyle Bittinger; Ying-Yu Chen; Sue A Keilbaugh; Meenakshi Bewtra; Dan Knights; William A Walters; Rob Knight; Rohini Sinha; Erin Gilroy; Kernika Gupta; Robert Baldassano; Lisa Nessel; Hongzhe Li; Frederic D Bushman; James D Lewis
Journal:  Science       Date:  2011-09-01       Impact factor: 47.728

Review 8.  Talking microbes: When gut bacteria interact with diet and host organs.

Authors:  Patrice D Cani; Amandine Everard
Journal:  Mol Nutr Food Res       Date:  2015-08-26       Impact factor: 5.914

9.  Humanized microbiota mice as a model of recurrent Clostridium difficile disease.

Authors:  James Collins; Jennifer M Auchtung; Laura Schaefer; Kathryn A Eaton; Robert A Britton
Journal:  Microbiome       Date:  2015-08-20       Impact factor: 14.650

10.  Diet and specific microbial exposure trigger features of environmental enteropathy in a novel murine model.

Authors:  Eric M Brown; Marta Wlodarska; Benjamin P Willing; Pascale Vonaesch; Jun Han; Lisa A Reynolds; Marie-Claire Arrieta; Marco Uhrig; Roland Scholz; Oswaldo Partida; Christoph H Borchers; Philippe J Sansonetti; B Brett Finlay
Journal:  Nat Commun       Date:  2015-08-04       Impact factor: 14.919

View more
  19 in total

Review 1.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

2.  Bacteriophages in the gastrointestinal tract and their implications.

Authors:  Marzanna Łusiak-Szelachowska; Beata Weber-Dąbrowska; Ewa Jończyk-Matysiak; Renata Wojciechowska; Andrzej Górski
Journal:  Gut Pathog       Date:  2017-08-10       Impact factor: 4.181

3.  The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment.

Authors:  Ira Ekmekciu; Eliane von Klitzing; Ulrike Fiebiger; Christian Neumann; Petra Bacher; Alexander Scheffold; Stefan Bereswill; Markus M Heimesaat
Journal:  Front Cell Infect Microbiol       Date:  2017-05-05       Impact factor: 5.293

4.  Efficacy of Phage Therapy in Controlling Rabbit Colibacillosis and Changes in Cecal Microbiota.

Authors:  Jian Zhao; Yan Liu; Chenwen Xiao; Shaojie He; Huochun Yao; Guolian Bao
Journal:  Front Microbiol       Date:  2017-05-29       Impact factor: 5.640

Review 5.  Enteric Pathogens and Their Toxin-Induced Disruption of the Intestinal Barrier through Alteration of Tight Junctions in Chickens.

Authors:  Wageha A Awad; Claudia Hess; Michael Hess
Journal:  Toxins (Basel)       Date:  2017-02-10       Impact factor: 4.546

Review 6.  Nutraceuticals: opening the debate for a regulatory framework.

Authors:  Antonello Santini; Silvia Miriam Cammarata; Giacomo Capone; Angela Ianaro; Gian Carlo Tenore; Luca Pani; Ettore Novellino
Journal:  Br J Clin Pharmacol       Date:  2018-02-14       Impact factor: 4.335

7.  Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats.

Authors:  Alessandra Consonni; Chiara Cordiglieri; Elena Rinaldi; Roberta Marolda; Ilaria Ravanelli; Elena Guidesi; Marina Elli; Renato Mantegazza; Fulvio Baggi
Journal:  Oncotarget       Date:  2018-04-27

8.  Epstein-Barr virus-immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice.

Authors:  Pascal Polepole; Alison Bartenslager; Yutong Liu; Thomas M Petro; Samodha Fernando; Luwen Zhang
Journal:  J Med Virol       Date:  2020-10-05       Impact factor: 20.693

9.  Draft Genome Sequences of the Probiotic Enterococcus faecalis Symbioflor 1 Clones DSM16430 and DSM16434.

Authors:  Moritz Fritzenwanker; Anindita Chakraborty; Torsten Hain; Kurt Zimmermann; Eugen Domann
Journal:  Genome Announc       Date:  2016-09-29

Review 10.  MicroRNAs-Based Inter-Domain Communication between the Host and Members of the Gut Microbiome.

Authors:  Maggie R Williams; Robert D Stedtfeld; James M Tiedje; Syed A Hashsham
Journal:  Front Microbiol       Date:  2017-09-27       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.